Truist Financial
AXSM icon

Truist Financial’s Axsome Therapeutics AXSM Stock Holding History

Truist Financial’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$634K Sell
2,590
-199
-7% -$43.2K ﹤0.01% 2047
2026
Q1 		$471K Sell
2,789
-266
-9% -$45.9K ﹤0.01% 2115
2025
Q4 		$558K Buy
3,055
+1,100
+56% +$154K ﹤0.01% 1987
2025
Q3 		$237K Buy
+1,955
New +$220K ﹤0.01% 2455
2025
Q2 		– Sell
-2,048
Closed -$239K – 2599
2025
Q1 		$239K Buy
+2,048
New +$233K ﹤0.01% 2270
2024
Q4 		– Sell
-21,083
Closed -$1.89M – 2520
2024
Q3 		$1.89M Hold
21,083
– – ﹤0.01% 1256
2024
Q2 		$1.7M Hold
21,083
– – ﹤0.01% 1349
2024
Q1 		$1.68M Sell
21,083
-3
-0% -$252 ﹤0.01% 1362
2023
Q4 		$1.68M Buy
+21,086
New +$1.41M ﹤0.01% 1357

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Truist Financial's AXSM Position: Q2 2026 in Review

Truist Financial reduced its Axsome Therapeutics (AXSM) stake by 7.1% in Q2 2026, selling an estimated $43.2K and leaving 2,590 shares worth $634K. The position accounts for ﹤0.01% of the portfolio, ranked #2047.

Truist Financial first reported a position in AXSM in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.89M in Q3 2024. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Truist Financial held 2,590 shares of Axsome Therapeutics worth $634K as of Q2 2026.
  • Truist Financial sold 199 Axsome Therapeutics shares in Q2 2026, an estimated $43.2K.
  • Axsome Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2047 holding.
  • Truist Financial first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 9 quarters since.
  • Truist Financial's Axsome Therapeutics position peaked at $1.89M in Q3 2024.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.